{"id":"NCT02696031","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis","officialTitle":"A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-29","primaryCompletion":"2019-07-01","completion":"2021-03-11","firstPosted":"2016-03-02","resultsPosted":"2020-08-07","lastUpdate":"2022-04-29"},"enrollment":555,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-radiographic Spondyloarthritis"],"interventions":[{"type":"DRUG","name":"Secukinumab","otherNames":["AIN457"]},{"type":"DRUG","name":"Placebo","otherNames":["AIN457"]}],"arms":[{"label":"Secukinumab, 150 mg Load (Core phase)","type":"EXPERIMENTAL"},{"label":"Secukinumab, 150 mg No Load (Core phase)","type":"EXPERIMENTAL"},{"label":"Placebo (Core phase)","type":"PLACEBO_COMPARATOR"},{"label":"Core Phase Responder 150 mg (Extension phase)","type":"EXPERIMENTAL"},{"label":"Core Phase Responder 300 mg (Extension phase)","type":"EXPERIMENTAL"},{"label":"Core Phase Non-Responder 300 mg (Extension phase)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and safety up to Week 104 (core phase) followed by an optional extension phase consisting of a 16-week randomized dose escalation treatment period and a continuous treatment period for up to Week 208","primaryOutcome":{"measure":"The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Secukinumab, Load, Core Phase","deltaMin":68,"sd":null},{"arm":"Secukinumab, No Load, Core Phase","deltaMin":70,"sd":null},{"arm":"Placebo, Core Phase","deltaMin":50,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0197"},{"comp":"OG001 vs OG002","p":"0.0146"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":6},"locations":{"siteCount":139,"countries":["United States","Australia","Austria","Belgium","Bulgaria","Czechia","France","Germany","Hungary","Israel","Italy","Japan","Mexico","Netherlands","Norway","Poland","Portugal","Russia","South Korea","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["40489668","37194094","35305260","34481517","32770640"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":48,"n":543},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Diarrhoea","Arthralgia"]}}